©Zhiguo He
The option concerns the clinical development (expected from 2020) and the commercialization of ELB011, a new first-in-class antibody in the treatment of wet AMD and other retinal vascular pathologies.
Théa Open Innovation has just signed a license and collaboration agreement for the OLX301A programme, an innovative new treatment for wet and dry age-related macular degeneration, with OliX Pharmaceuticals, a clinical stage pharmaceutical company which develops treatments for retinal vascular diseases in particular.